Outset Medical, Inc. (NASDAQ:OM – Get Free Report) CFO Renee Gaeta sold 4,543 shares of the company’s stock in a transaction on Monday, August 17th. The stock was sold at an average price of $4.39, for a total value of $19,943.77. Following the transaction, the chief financial officer owned 180,840 shares of the company’s stock, valued at approximately $793,887.60. The trade was a 2.45% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards.
Renee Gaeta also recently made the following trade(s):
- On Wednesday, June 3rd, Renee Gaeta sold 17,672 shares of Outset Medical stock. The shares were sold at an average price of $4.94, for a total transaction of $87,299.68.
Outset Medical Stock Performance
Shares of NASDAQ OM traded down $0.33 during midday trading on Tuesday, hitting $4.18. 143,860 shares of the company’s stock were exchanged, compared to its average volume of 407,222. Outset Medical, Inc. has a twelve month low of $3.00 and a twelve month high of $16.16. The firm has a market cap of $78.57 million, a P/E ratio of -1.02 and a beta of 1.96. The stock’s 50 day moving average price is $4.58 and its 200-day moving average price is $4.24. The company has a debt-to-equity ratio of 1.03, a current ratio of 5.19 and a quick ratio of 4.11.
Hedge Funds Weigh In On Outset Medical
Several institutional investors and hedge funds have recently modified their holdings of OM. Los Angeles Capital Management LLC acquired a new position in Outset Medical in the fourth quarter worth approximately $29,000. Legal & General Group Plc acquired a new stake in Outset Medical in the second quarter valued at approximately $34,000. BNP Paribas Financial Markets grew its position in Outset Medical by 7,013.8% in the second quarter. BNP Paribas Financial Markets now owns 2,063 shares of the company’s stock worth $40,000 after acquiring an additional 2,034 shares in the last quarter. Hsbc Holdings PLC bought a new stake in Outset Medical in the fourth quarter worth approximately $46,000. Finally, HRT Financial LP acquired a new position in shares of Outset Medical during the 4th quarter worth $58,000.
Analysts Set New Price Targets
OM has been the topic of several research reports. TD Cowen reaffirmed a “buy” rating on shares of Outset Medical in a report on Friday, May 8th. Weiss Ratings upgraded Outset Medical from a “sell (e+)” rating to a “sell (d-)” rating in a report on Friday, August 7th. Finally, Wall Street Zen raised Outset Medical from a “sell” rating to a “hold” rating in a research report on Saturday. Three research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, Outset Medical currently has an average rating of “Hold” and a consensus target price of $10.00.
View Our Latest Stock Report on OM
About Outset Medical
Outset Medical is a medical technology company specializing in innovations for renal care. The company’s flagship offering, the Tablo Hemodialysis System, is designed to streamline and simplify dialysis treatment across acute and outpatient settings. By integrating water purification, dialysate production, and treatment monitoring into a single device, Tablo aims to reduce the complexity and logistical burden traditionally associated with hemodialysis therapy.
Tablo’s modular design allows for rapid setup and flexible deployment in hospitals, clinics, long‐term care facilities and emergency response scenarios.
Further Reading
- Five stocks we like better than Outset Medical
- The AI Boom Is Turning This Cable Maker Into a Stock to Watch
- A Star Investor Just Trimmed Amazon—Here’s What It means
- Wendy’s Deal Buzz May Give Fast-Food Investors a New Reason to Look
- Home Depot Analysts See a Path to $375 and Beyond
Receive News & Ratings for Outset Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Outset Medical and related companies with MarketBeat.com's FREE daily email newsletter.
